Chromologic LLC SBIR Phase I Award, February 2022
A SBIR Phase I contract was awarded to Chromologic Llc in February, 2022 for $167,470.0 USD from the U.S. Department of Defense and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
All edits
Chromologic LLC SBIR Phase I Award, February 2022
To meet CBD’s need for a multi-dose formulation of scopolamine hydrobromide trihydrite ChromoLogic proposes to develop a vial add-on containing a self-decontamination cap with a self-healing material to eliminate evaporation and contamination risks through needle punctures in the septum. CL will also perform forced degradation and stability tests with a panel of preservatives to select optimal preservative/concentration and achieve target shelf-life. Overall, CL plans to work with the CBD to ensure this product is an amendment to their already existing FDA process for approval of their single-dose formulation.
Find more entities like Chromologic LLC SBIR Phase I Award, February 2022
